Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Diet and lifestyle considerations for patients with prostate cancer.

Zuniga KB, Chan JM, Ryan CJ, Kenfield SA.

Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30247-9. doi: 10.1016/j.urolonc.2019.06.018. [Epub ahead of print] Review.

PMID:
31327752
2.

The test for decision-making capacity in common law countries is not the test outlined by Zhong et al.

Ryan CJ.

Br J Psychiatry. 2019 Aug;215(2):502. doi: 10.1192/bjp.2019.142. No abstract available.

PMID:
31288881
3.

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.

Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]

PMID:
31171481
4.

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T.

Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15.

PMID:
31100231
5.

Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?

Rao A, Vapiwala N, Schaeffer EM, Ryan CJ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:309-320. doi: 10.1200/EDBK_239041. Epub 2019 May 17.

PMID:
31099652
6.

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 Jun;114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11.

7.

Association between suicidal ideation and suicide: meta-analyses of odds ratios, sensitivity, specificity and positive predictive value - ERRATUM.

McHugh CM, Corderoy A, Ryan CJ, Hickie IB, Large MM.

BJPsych Open. 2019 Mar;5(2):e24. doi: 10.1192/bjo.2019.15. No abstract available.

8.

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S; From The Alliance for Clinical Trials in Oncology Genitourinary Committee.

Prostate Cancer Prostatic Dis. 2019 May 3. doi: 10.1038/s41391-019-0152-3. [Epub ahead of print]

PMID:
31053766
9.

SMS SOS: a randomized controlled trial to reduce self-harm and suicide attempts using SMS text messaging.

Stevens GJ, Hammond TE, Brownhill S, Anand M, de la Riva A, Hawkins J, Chapman T, Baldacchino R, Micallef JA, Andepalli J, Kotak A, Gunja N, Page A, Gould G, Ryan CJ, Whyte IM, Carter GL, Jones A.

BMC Psychiatry. 2019 Apr 18;19(1):117. doi: 10.1186/s12888-019-2104-9.

10.

The Three Rs for Preventing Heart Failure Readmission: Review, Reassess, and Reeducate.

Ryan CJ, Bierle RS, Vuckovic KM.

Crit Care Nurse. 2019 Apr;39(2):85-93. doi: 10.4037/ccn2019345.

PMID:
30936132
11.

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16.

12.

Is legislative reform translating into recovery-orientated practice and better protection of rights?

Ryan CJ.

Aust N Z J Psychiatry. 2019 May;53(5):382-383. doi: 10.1177/0004867419828482. Epub 2019 Feb 13. No abstract available.

PMID:
30754990
13.

Association between suicidal ideation and suicide: meta-analyses of odds ratios, sensitivity, specificity and positive predictive value.

McHugh CM, Corderoy A, Ryan CJ, Hickie IB, Large MM.

BJPsych Open. 2019 Mar;5(2):e18. doi: 10.1192/bjo.2018.88. Erratum in: BJPsych Open. 2019 Mar;5(2):e24.

14.

Acute Coronary Syndrome Symptom Clusters: Illustration of Results Using Multiple Statistical Methods.

Ryan CJ, Vuckovic KM, Finnegan L, Park CG, Zimmerman L, Pozehl B, Schulz P, Barnason S, DeVon HA.

West J Nurs Res. 2019 Jul;41(7):1032-1055. doi: 10.1177/0193945918822323. Epub 2019 Jan 22.

PMID:
30667327
15.

Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making.

Morgans AK, Ryan CJ.

Eur Urol. 2019 Jun;75(6):948-949. doi: 10.1016/j.eururo.2019.01.005. Epub 2019 Jan 12. No abstract available.

PMID:
30642609
16.

Issues pertaining to expert evidence and the reasoning about punishment in a neuroscience-based sentencing appeal.

McCay A, Ryan CJ.

Int J Law Psychiatry. 2018 Dec 24:101409. doi: 10.1016/j.ijlp.2018.11.006. [Epub ahead of print] Review.

PMID:
30591221
17.

How Should Physicians Use Their Authority to Name a Stigmatizing Diagnosis and Respond to a Patient's Experience?

Bartels J, Ryan CJ.

AMA J Ethics. 2018 Dec 1;20(12):E1119-1125. doi: 10.1001/amajethics.2018.1119.

18.

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.

Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ.

Cancer. 2019 Feb 1;125(3):453-462. doi: 10.1002/cncr.31826. Epub 2018 Nov 16.

PMID:
30444526
19.

Symptom Cluster Science in Chronic Kidney Disease: A Literature Review.

Lockwood MB, Chung S, Puzantian H, Bronas UG, Ryan CJ, Park C, DeVon HA.

West J Nurs Res. 2019 Jul;41(7):1056-1091. doi: 10.1177/0193945918808766. Epub 2018 Oct 31.

PMID:
30378466
20.

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr.

Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

PMID:
30373918
21.

Systems biology: old news or new stimulus for biochemistry.

Kolch W, Fey D, Ryan CJ.

Essays Biochem. 2018 Oct 26;62(4):483-486. doi: 10.1042/EBC20180002. Print 2018 Oct 26.

PMID:
30366987
22.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

23.

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R.

Clin Genitourin Cancer. 2019 Feb;17(1):e92-e96. doi: 10.1016/j.clgc.2018.09.013. Epub 2018 Sep 24.

PMID:
30327180
24.

Synthetic Lethality and Cancer - Penetrance as the Major Barrier.

Ryan CJ, Bajrami I, Lord CJ.

Trends Cancer. 2018 Oct;4(10):671-683. doi: 10.1016/j.trecan.2018.08.003. Epub 2018 Sep 15. Review.

PMID:
30292351
25.

Our duty to know and understand the law.

Ryan CJ.

Australas Psychiatry. 2018 Oct;26(5):453-454. doi: 10.1177/1039856218799922. No abstract available.

PMID:
30269565
26.

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:363-371. doi: 10.1200/EDBK_200967. Review.

PMID:
30231388
27.

Organizational Factors Associated With Technical Efficiency of Nursing Care in US Intensive Care Units.

Min A, Scott LD, Park C, Vincent C, Ryan CJ.

J Nurs Care Qual. 2019 Jul/Sep;34(3):242-249. doi: 10.1097/NCQ.0000000000000362.

PMID:
30211776
28.

Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease.

Carr JS, Bonham LW, Morgans AK, Ryan CJ, Yokoyama JS, Geier EG; Alzheimer’s Disease Neuroimaging Initiative.

Front Neurosci. 2018 Aug 7;12:529. doi: 10.3389/fnins.2018.00529. eCollection 2018.

29.

BRCAness and prostate cancer: diagnostic and therapeutic considerations.

Dhawan M, Ryan CJ.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):488-498. doi: 10.1038/s41391-018-0069-2. Epub 2018 Aug 21. Review.

PMID:
30131605
30.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

31.

Community treatment orders are (somewhat) effective: Their future in the context of rights-based mental health law.

Ryan CJ.

Aust N Z J Psychiatry. 2019 Jan;53(1):11-12. doi: 10.1177/0004867418791300. Epub 2018 Aug 9. No abstract available.

PMID:
30091367
32.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

33.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

34.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

35.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.

JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.

36.

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.

Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ.

Oncogene. 2018 Oct;37(43):5701-5718. doi: 10.1038/s41388-018-0368-z. Epub 2018 Jun 18.

37.

Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.

Kornberg Z, Chou J, Feng FY, Ryan CJ.

Ann Transl Med. 2018 May;6(9):161. doi: 10.21037/atm.2018.05.06. Review.

38.

Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F.

BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.

39.

At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.

Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ.

Oncologist. 2018 Oct;23(10):1242-1249. doi: 10.1634/theoncologist.2017-0628. Epub 2018 Apr 26.

PMID:
29700209
40.

Impact of Medicare Advantage penetration and hospital competition on technical efficiency of nursing care in US intensive care units.

Min A, Scott LD, Park C, Vincent C, Ryan CJ, Lee T.

Int J Health Plann Manage. 2018 Apr 10. doi: 10.1002/hpm.2528. [Epub ahead of print]

PMID:
29635856
41.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

PMID:
29630978
42.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

43.

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ.

Oncologist. 2018 Jun;23(6):656-e64. doi: 10.1634/theoncologist.2017-0624. Epub 2018 Feb 27.

44.

Community treatment orders: towards a new research agenda.

Brophy L, Edan V, Gooding P, McSherry B, Burkett T, Carey S, Carroll A, Callaghan S, Finch A, Hansford M, Hanson S, Kisely S, Lawn S, Light E, Maher S, Patel G, Ryan CJ, Saltmarsh K, Stratford A, Tellez JJ, Toko M, Weller P.

Australas Psychiatry. 2018 Jun;26(3):299-302. doi: 10.1177/1039856218758543. Epub 2018 Feb 20.

PMID:
29463100
45.

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L.

Clin Genitourin Cancer. 2018 Jun;16(3):184-190.e2. doi: 10.1016/j.clgc.2017.12.004. Epub 2017 Dec 27.

PMID:
29352713
46.

Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels.

Campbell J, Ryan CJ, Lord CJ.

Methods Mol Biol. 2018;1711:83-99. doi: 10.1007/978-1-4939-7493-1_5.

PMID:
29344886
47.

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC; Prostate Cancer DREAM Challenge Community.

JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.17.00018.

48.

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.

Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159.

49.

Can we usefully stratify patients according to suicide risk?

Large MM, Ryan CJ, Carter G, Kapur N.

BMJ. 2017 Oct 17;359:j4627. doi: 10.1136/bmj.j4627. No abstract available.

PMID:
29042363
50.

A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events.

Ryan CJ, Kennedy S, Bajrami I, Matallanas D, Lord CJ.

Cell Syst. 2017 Oct 25;5(4):399-409.e5. doi: 10.1016/j.cels.2017.09.011. Epub 2017 Oct 11.

Supplemental Content

Support Center